Teva Announces Tentative Approval Of Generic Femara(R) Tablets
Main Category: Breast CancerAlso Included In: Regulatory Affairs / Drug Approvals; Cancer / Oncology
Article Date: 22 Jan 2010 - 21:00 PDT
'Teva Announces Tentative Approval Of Generic Femara(R) Tablets'
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
5 (1 votes) |
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
The brand product had annual sales of approximately $556 million in the United States, based on IMS sales data.
Source
Teva Pharmaceutical Industries Ltd.
Visit our breast cancer section for the latest news on this subject.
MLA
26 May. 2012. <http://www.medicalnewstoday.com/releases/176867.php>
APA
http://www.medicalnewstoday.com/releases/176867.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Teva Announces Tentative Approval Of Generic Femara(R) Tablets'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





